|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Novartis AG (NVS), a developer and manufacturer of pharmaceuticals and nutritional products. |
|---|---|
| Transferring Party | OTC Brand Portfolio of Bristol-Myers-Squibb Company, a major producer of pharmaceuticals and other healthcare related products. |
| Sector | Biopharmaceuticals |
| Date | July 20, 2005 |
| Analysis Novartis acquires the rights to BMS' North American OTC brand portfolio for approximately $660 million ($258 million in sales). Gives Novartis entre into the US adult analgesic market (the largest OTC market with US sales in 2004 estimated at $2 billion). Other acquired brands are No-Doz, Comtrex, and Mineral Ice. The Deal enables BMS to focus on prescription drugs and invest in research and development. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |